Review highlights ZIF-based nanoplatforms for drug delivery and biosensing in endocrine diseases, indicating innovative treatment avenues.
metabolic mechanisms, and scalable preparation remain to be addressed. This review explicitly identifies that ZIF-based nanoplatforms, particularly through their stimulus-responsive drug delivery and high-sensitivity biosensing capabilities, have achieved significant and unique accomplishments in developing intelligent diagnostic and therapeutic strategies for endocrine diseases, which is highly consistent with the scope of this journal focusing on applied biomaterials.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: